Figure 7.

Systemic delivery and treatment outcome using MV-NIS infected RT10-MM1 cell carries in measles naive and passively immunized SCID mice-bearing disseminated KAS 6/1 myeloma disease. (a) Bioluminescent images showing amount and location of myeloma disease in mice over time. (b) Quantitation of Fluc activity as a measurement of disease burden, and (c) Kaplan–Meier survival curves of mice in the various treatment groups. Fluc, firefly luciferase; MM, multiple myeloma; MV, measles virus; SCID, severe combined immunodeficiency.